A dose-finding Phase 1 study of TAS-120 in patients with advanced solid tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-related abnormalities followed by a Phase 2 study in patients with advanced solid tumors with FGF/FGFR-related abnormalities

Trial Profile

A dose-finding Phase 1 study of TAS-120 in patients with advanced solid tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-related abnormalities followed by a Phase 2 study in patients with advanced solid tumors with FGF/FGFR-related abnormalities

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs TAS 120 (Primary)
  • Indications Multiple myeloma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 25 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 12 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top